GREATER GLASGOW HEALTH BOARD

Their core work

Greater Glasgow Health Board (NHS Greater Glasgow and Clyde) is the largest NHS board in Scotland, providing healthcare to over 1.2 million people. In H2020, they contribute real-world clinical data, patient cohorts, and clinical expertise to large-scale European research consortia focused on inflammatory diseases, neurodevelopment, and precision medicine. Their value lies in providing access to a large, diverse patient population and established clinical infrastructure for multi-centre trials and registries.

What they specialise in

How they've shifted over time

Early participation (2015–2017) centred on organ-specific clinical conditions: paediatric inflammatory bowel disease treatment safety, endocrine hypertension, and cardiogenic shock interventions. From 2018 onward, the focus shifted toward systemic immune-mediated diseases, precision medicine approaches (disease trajectories, predictive modelling, stratification), and digital health measurement tools. This evolution mirrors the broader clinical research trend from disease-specific registries toward cross-disease mechanistic understanding and digital patient monitoring.

Moving toward precision medicine and digital health endpoints across multiple inflammatory and immune-mediated conditions, making them a strong partner for projects needing real-world clinical validation of stratification tools.

How they like to work

GGHB operates almost exclusively as a third-party contributor (7 of 8 projects), providing clinical sites, patient data, and domain expertise to large consortia rather than leading or co-designing research programmes. Their 233 unique partners across 29 countries indicate they are embedded in major European clinical networks but in a supporting role. This makes them a low-risk, reliable clinical partner — they bring patients and data without competing for scientific leadership.

Connected to 233 unique partners across 29 countries, reflecting involvement in several very large IMI-style and RIA consortia rather than deep bilateral relationships. Their network spans Western and Southern Europe with global reach through projects like HEADSpAcE (South America–Europe collaboration).

What sets them apart

As Scotland's largest NHS board, GGHB offers what universities and research institutes cannot: direct access to a large, ethnically diverse patient population within a single integrated healthcare system. Their consistent role as a third-party clinical site across multiple disease areas makes them particularly valuable for projects needing multi-centre trial sites with established ethical approvals and data governance infrastructure. They are one of the few UK public health bodies with sustained H2020 participation across both paediatric and adult disease cohorts.

Highlights from their portfolio

• PIBD-SETQuality
  Their only directly funded H2020 project (EUR 431K), building a pan-European registry for paediatric inflammatory bowel disease treatment safety — the project where GGHB had the most active role.
• AIMS-2-TRIALS
  One of Europe's largest autism research initiatives (running to 2026), demonstrating GGHB's capacity to contribute clinical data to flagship programmes in neurodevelopment.
• 3TR
  Ambitious cross-disease project on treatment non-response using single-cell data and integrative genomics — represents GGHB's shift toward precision medicine approaches.